|
Madeira Therapeutics Selected to Present at the 2010 World’s Best Technologies Showcase
WBT2010
LEAWOOD, Kan.--(BUSINESS WIRE)--Madeira Therapeutics, a Kansas-based company specializing in pediatric pharmaceuticals, is one of over 100 companies and technology innovators from across the nation and around the world that will compete for top honors at the 2010 World’s Best Technologies (WBT) Showcase, March 16-17, in Arlington, Texas.
Madeira Therapeutics currently has two pediatric products in development: MT-001, the first ever liquid preparation of a cholesterol-lowering statin for children and the elderly, and MT-003, a liquid analgesic for the treatment of acute pain.
“Companies presenting at the WBTshowcase leave with new knowledge and contacts to take their technologies to the market and beyond,” said WBTshowcase CEO Paul Huleatt. “The conventional wisdom for venture capital is that a down economy can be a great time to invest. The pace of new innovations accelerates, the best deals rise quickly to the top and sophisticated investors receive great value for their money.”
Madeira Therapeutics’ two pediatric products will be rigorously prepped by WBTshowcase commercialization experts. Participating technologies are selected by - and presented to - over 100 seasoned venture investors and Fortune 500 licensing scouts representing a variety of industries, each supported by private funding, federal R&D grants or both.
“With the rise of childhood obesity, the need for a pediatric statin is critical,” stated Madeira Therapeutics CEO Pete Joiner. “We are grateful for the investors who are willing to join with us and address these issues in our society today.”
About Madeira Therapeutics
Madeira Therapeutics, LLC, is a privately held, specialty pharmaceutical company focused on providing safe and effective medicine to pediatric and geriatric patients, parents and the healthcare professionals who serve them. The Madeira strategy focuses on reformulating adult drugs for better dosage control in children. Madeira utilizes the FDA’s 505(b)(2) approval method, which relies in part on the regulatory agency’s findings for a drug previously approved for adults, thereby shortcutting IND approval by years and saving tens of millions of dollars in development costs. For more information, please visit http://www.madeiratherapeutics.com/.
Media Contact:
Patti D. Hill
Penman PR
512.218.0401
patti@penmanpr.com
|